IMAGE: Dr. Maya Guglin chaired a study demonstrating the effectiveness of beta blockers and ACE inhibitors to prevent cardio toxicity in certain breast cancer patients. view more
Credit: Uk HealthCare
ORLANDO, Fl. (Mar. 11, 2018) – Data released today from a large multi-center study provides a view into the effectiveness of two drugs used to prevent heart problems resulting from breast cancer treatment.
The data was presented at the American College of Cardiology’s 67th Annual Scientific Session, one of the most influential medical symposia on heart-related topics.
“This data is the crucial first step towards establishing a new standard of care to reduce the risk of cardiotoxicity for patients undergoing treatment for HER2-positive breast cancer,” said study chair Dr. Maya Guglin of the University of Kentucky’s Gill Heart & Vascular Institute.
Chemotherapy drug Herceptin was first approved by the FDA in 1998 to treat an aggressive form of breast cancer called HER2-positive. Its stunning success at reducing cancer recurrence and improving survival came at a cost, however: one in four women develop potentially dangerous heart problems. Physicians began suspending Herceptin treatment or reducing the frequency of treatment if a patient’s ejection fraction (a measure of the heart’s ability to
Article originally posted at